Therapeutics that leverage protein degradation as their primary mechanism of action appear to be a validated new therapeutic modality. The current clinical molecules are focused on degrading ...

As gene therapies continue to advance, the demand for scalable, reproducible, and efficient potency assays is rapidly increasing—especially for adeno-associated virus (AAV) vectors. Accurate ...